A review and meta-analysis of colorectal cancer utilities

Medical Decision Making

Volumn 34, Issue 6, 2014, Pages 809-818

  Djalalov, Sandjar ^a,c,g   Rabeneck, Linda ^b,c   Tomlinson, George ^b,f   Bremner, Karen E ^d   Hilsden, Robert ^e   Hoch, Jeffrey S ^a,b,c,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Pharmacoeconomics Research Unit   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g Canadian Centre for Applied Research in Cancer Control (ARCC)   (Canada)

Author keywords

Colorectal cancer; Meta analysis; Preferences; Quality of life; Utility assessment

Indexed keywords

CANCER STAGING; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; HUMAN; META ANALYSIS; PATHOLOGY; PSYCHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; TIME FACTOR;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; NEOPLASM STAGING; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84907055916     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X14536779     Document Type: Review

References (45)

1. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1688-94.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-5.
3. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2004. Available from: URL: http://www.nice.org.uk/media/ B52/A7/TAMethodsGuideUpdated June2008.pdf
4. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
5. College voor Zorgverzekeringen. Guidelines for pharmacoeconomic research: updated version 2006. Available from: URL: http://www.cvz.nl/binaries/content/ documents/cvzinternet/en/documents/procedures/guidelines-pharmacoeconomic- research .pdf
6. International Society for Pharmacoeconomics and Outcomes Research. General guidelines for economic evaluations from the Pharmaceutical Benefits Board 2003. Available from: URL: http://www.ispor.org/peguidelines/source/ Guidelines-in-Sweden.pdf
7. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18(18): 3302-17.
8. Drummond MF, Sculpher MJ, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford University Press; 2005.
9. Dolan P. Modelling valuations for health states: the effect of duration. Health Policy. 1996;38(3):189-203.
10. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999; 94(6):1650-7.
11. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294-303.
12. Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis . BMJ. 2009; 339:b2688.
13. Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791-9.
14. Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med Decis Making. 2007;27(3):288-98.
15. Tengs TO, Lin TH.Ameta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22(6):475-81.
16. Janson M, Lindholm E, Anderberg B, Haglind E. Randomized trial of health-related quality of life after open and laparoscopic surgery for colon cancer. Surg Endosc. 2007;21(5):747-53.
17. Peasgood T, Herrmann K, Kanis JA, Brazier JE.An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853-68.
18. Doornebosch PG, Tollenaar RA, Gosselink MP, et al. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. Colorectal Dis. 2007;9(6):553-8.
19. Starling N, Tilden D, White J, Cunningham D. Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 2007;96(2):206-12.
20. Gosselink MP, Busschbach JJ, Dijkhuis CM, Stassen LP, Hop WC, Schouten WR. Quality of life after total mesorectal excision for rectal cancer. Colorectal Dis. 2006;8(1):15-22.
21. Sharma A, Sharp DM, Walker LG, Monson JR. Predictors of early postoperative quality of life after elective resection for colorectal cancer. Ann Surg Oncol. 2007;14(12):3435-42.
22. Wilson TR, Alexander DJ, Kind P. Measurement of healthrelated quality of life in the early follow-up of colon and rectal cancer. Dis Colon Rectum. 2006;49(11):1692-702.
23. van den Brink M, van den Hout WB, Stiggelbout AM, et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol. 2004;22(2):244-53.
24. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97(5):1228-34.
25. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum. 2000;43(12):1695-701.
26. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol. 1997;8(1): 65-70.
27. Langenhoff BS, Krabbe PF, Peerenboom L, Wobbes T, Ruers TJ. Quality of life after surgical treatment of colorectal liver metastases. Br J Surg. 2006;93(8):1007-14.
28. Amemiya T, Oda K, Ando M, et al. Activities of daily living and quality of life of elderly patients after elective surgery for gastric and colorectal cancers. Ann Surg. 2007;246(2):222-8.
29. Stiggelbout AM, de Haes JC, Kiebert GM, Kievit J, Leer JW. Tradeoffs between quality and quantity of life: development of the QQ Questionnaire for Cancer Patient Attitudes. Med Decis Making. 1996;16(2):184-92.
30. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191-200.
31. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010; 10(5):553-66.
32. Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Making. 2010;30(6):685-93.
33. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and costeffectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2003;7(32):1-93.
34. Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res. 2009;18(8):1095-103.
35. Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res. 2010;19(3):391-400.
36. Wiering B, Adang EM, van der Sijp JR, et al. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun. 2010;31(11): 938-44.
37. Masya LM, Young JM, Solomon MJ, Harrison JD, Dennis RJ, Salkeld GP. Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. Dis Colon Rectum. 2009; 52(12):1994-2002.
38. Dranitsaris G, Ortega A, Lubbe MS, Truter I. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. J Oncol Pharm Pract. 2012;18(1):57-67.
39. Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB. Improving patient access to cancer drugs in India: using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011;27(1):23-30.
40. American Joint Committee on Cancer. AJCC Cancer Staging Handbook from the AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
41. Mayo Clinic. Colon cancer definition. Available from: URL: http://www.mayoclinic.com/health/colon-cancer/DS00035
42. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2013. Available from: URL: http://www.R-project.org/
43. Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. DSC 2003 Working Papers. Available from: URL: http://www.ci.tuwien.ac.at/Conferences/DSC-2003/Drafts/Plummer.pdf
44. Sumner W, Nease R, Littenberg B. U-titer: a utility assessment tool. Proc Annu Symp Comput Appl Med Care. 1991:701-5.
45. Lenert LA. The reliability and internal consistency of an Internet-capable computer program for measuring utilities. Qual Life Res. 2000;9(7):811-7.